

- Supraorbital neurostimulation with the Cefaly® (Cefaly Technology sprl, Herstal, Belgium) device provides safe and effective preventive treatment in episodic migraine.
- Daily 20-minute use of the Cefaly device has been shown to be associated with significantly reduced migraine attacks and headache days.
- The Cefaly device has been shown to allow for a significant reduction in the intake of acute anti-migraine drugs.
- The efficacy/safety ratio of Cefaly seems superior to that of most preventive pharmacotherapies.

This summary slide represents the opinions of the authors. No funding was received for publication of this review. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).